Rankings
▼
Calendar
RIGL FY 2021 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$541M
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$149M
+37.4% YoY
Gross Profit
$148M
99.3% margin
Operating Income
-$12M
-8.4% margin
Net Income
-$18M
-12.0% margin
EPS (Diluted)
$-1.10
Cash Flow
Operating Cash Flow
$6M
Free Cash Flow
$5M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$167M
Total Liabilities
$137M
Stockholders' Equity
$30M
Cash & Equivalents
$19M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$149M
$109M
+37.4%
Gross Profit
$148M
$108M
+37.5%
Operating Income
-$12M
-$29M
+56.9%
Net Income
-$18M
-$30M
+39.8%
← Q4 2020
All Quarters
Q1 2021 →